P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE von Vlachová, M., Štork, M., Ševčíková, S., Jelínek, T., Minařík, J., Radocha, J., Krhovská, P., Pospíšilová, L., Špička, I., Straub, J., Pavlíček, P., Jungová, A., Sandecká, V., Maisnar, V., Hájek, R., Pour, L.

Volltext

Liquid Biopsies - the Clinics and the Molecules von Kubaczková, V, Sedlarikova, L, Bollová, B, Sandecká, V, Stork, M, Pour, L, Sevcikova, S

Volltext

Waldenström’s macroglobulinemia – clinical symptoms and review of therapy yesterday, today and tomorrow von Adam, Zdeněk, Pour, Luděk, Zeman, David, Krejčí, Marta, Boichuk, Ivanna, Krejčí, Martin, Štork, Martin, Sandecká, Viera, Král, Zdeněk

Volltext

Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues von Klincová, M, Sandecká, V, Mikuláiová, A, Radocha, J, Maisnar, V, Hájek, R

Volltext

Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience von Sandecka, V, Adam, Z, Krejci, M, Stork, M, Rehak, Z, Koukalova, R, Sevcikova, S, Brozova, L, Kral, Z, Mayer, J, Pour, L

Volltext

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients von Stork, M, Sevcikova, S, Adam, Z, Krejci, M, Sandecka, V, Kral, Z, Brozova, L, Velichova, R, Pour, L

Volltext

Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories von Pika, T, Lochman, P, Sandecka, V, Maisnar, V, Minarik, J, Tichy, M, Zapletalova, J, Solcova, L, Scudla, V, Hajek, R

Volltext

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse von Pour, Ludek, Sevcikova, Sabina, Greslikova, Henrieta, Kupska, Renata, Majkova, Petra, Zahradova, Lenka, Sandecka, Viera, Adam, Zdenek, Krejci, Marta, Kuglik, Petr, Hajek, Roman

Volltext

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results von Zahradova, L, Mollova, K, Ocadlikova, D, Kovarova, L, Adam, Z, Krejci, M, Pour, L, Krivanova, A, Sandecka, V, Hajek, R

Volltext

Scleredema associated with multiple myeloma or MGUS: treatment report of four cases von Krejci, M, Adam, Z, Pour, L, Michalkova, E, Sandecka, V, Szturz, P, Kral, Z, Mayer, J

Volltext

Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens von Adam, Z, Stork, M, Pour, L, Krejčí, M, Zahradová, L, Sandecká, V, Hájek, R, Cermáková, Z, Pospíšilová, Y, Navrátil, M, Král, Z, Mayer, J

Volltext

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma von Stork, Martin, Sevcikova, Sabina, Krejci, Marta, Adam, Zdenek, Sandecka, Viera, Maisnar, Vladimir, Radocha, Jakub, Spicka, Ivan, Straub, Jan, Minarik, Jiri, Pika, Tomas, Jungova, Alexandra, Gregora, Evzen, Pavlicek, Petr, Vrabel, David, Jarkovsky, Jiri, Brozova, Lucie, Jelinek, Tomas, Hajek, Roman, Pour, Ludek

Volltext

Bortezomib-Based Induction Treatment for Patients with Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation: A Retrospective Multicenter Study in Czech Republic von Sandecka, Viera, Pour, Ludek, Sevcikova, Sabina, Brozova, Lucie, Straub, Jan, Scudla, Vlastimil, Maisnar, Vladimir, Pavlicek, Petr, Adam, Zdenek, Krejci, Marta, Stork, Martin, Jelinek, Tomas, Plonkova, Hana, Hajek, Roman

Volltext

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma von Král, Zdeněk, Adam, Zdeněk, Folber, František, Moulis, Mojmír, Tomíška, Miroslav, Říhová, Lucie, Štork, Martin, Buliková, Alena, Pour, Luděk, Krejčí, Marta, Sandecká, Viera, Koukalová, Renata, Řehák, Zdeněk, Čermáková, Zdeňka

Volltext

Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse von Krejci, Marta, Scudla, Vlastimil, Tothova, Elen, Schutzova, Miroslava, Koza, Vladimir, Adam, Zdenek, Krivanova, Andrea, Pour, Ludek, Buchler, Tomas, Sandecka, Viera, Kralova, Dana, Zahradova, Lenka, Vorlicek, Jiri, Mayer, Jiri, Hajek, Roman

Volltext

A251 Better Efficacy/Toxicity Ratio of Velcade-Based Regimens von Hajek, R, Zahradova, L, Gregora, E, Schutzova, M, Koza, V, Pavlicek, P, Pour, L, Krejci, M, Sandecka, V, Krivanova, A, al Sahmani, M, Kralova, D, Adam, Z

Volltext

B226 High HGF Levels are Associated with Response to Bortezomib von Svachova, H, Al Sahmani, M, Hajek, R, Pour, L, Kralova, D, Nemec, P, Adam, Z, Krejci, M, Sandecka, V, Krivanova, A

Volltext

A185 High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment von Pour, L, Svachova, H, Nemec, P, Adam, Z, Krejci, M, Sandecka, V, Holanek, M, Kovarova, L, Zahradova, L, Penka, M, Hajek, R

Volltext

B228 Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens von Nemec, P, Greslikova, H, Smetana, J, Zaoralova, R, Kupska, R, Berankova, K, Filkova, H, Kralova, D, Krejci, M, Pour, L, Zahradova, L, Sandecka, V, Adam, Z, Kuglik, P, Hajek, R

Volltext